KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Daily Values

Growth Metrics

Assets (QoQ)Assets Growth (1y)Assets Growth (3y)Assets Growth (5y)Capital Expenditures (QoQ)Capital Expenditures Growth (1y)Capital Expenditures Growth (3y)Capital Expenditures Growth (5y)Cash & Equivalents (QoQ)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash & Equivalents Growth (5y)Cash from Investing Activities (QoQ)Cash from Investing Activities Growth (1y)Cash from Investing Activities Growth (3y)Cash from Investing Activities Growth (5y)Cash from Operations (QoQ)Cash from Operations Growth (1y)Cash from Operations Growth (3y)Cash from Operations Growth (5y)Dividends Paid - Common (QoQ)Dividends Paid - Common Growth (1y)Dividends Paid - Common Growth (3y)EBIT (QoQ)EBIT Growth (1y)EBIT Growth (3y)EBIT Growth (5y)EBIT Margin (QoQ)EBIT Margin Growth (1y)EBIT Margin Growth (3y)EBIT Margin Growth (5y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBITDA Margin Growth (3y)EBITDA Margin Growth (5y)EBT (QoQ)EBT Growth (1y)EBT Growth (3y)EBT Growth (5y)EBT Margin (QoQ)EBT Margin Growth (1y)EBT Margin Growth (3y)EBT Margin Growth (5y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Basic) Growth (3y)EPS (Basic) Growth (5y)EPS (Weighted Average and Diluted) (QoQ)EPS (Weighted Average and Diluted) Growth (1y)EPS (Weighted Average and Diluted) Growth (3y)EPS (Weighted Average and Diluted) Growth (5y)Enterprise Value (QoQ)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)FCF Margin (QoQ)FCF Margin Growth (1y)FCF Margin Growth (3y)FCF Margin Growth (5y)FCF Payout Ratio (QoQ)FCF Payout Ratio Growth (1y)FCF Payout Ratio Growth (3y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Free Cash Flow Growth (3y)Free Cash Flow Growth (5y)Gross Margin (QoQ)Gross Margin Growth (1y)Gross Margin Growth (3y)Gross Margin Growth (5y)Gross Profit (QoQ)Gross Profit Growth (1y)Gross Profit Growth (3y)Gross Profit Growth (5y)Interest Coverage Ratio (QoQ)Interest Coverage Ratio Growth (1y)Interest Coverage Ratio Growth (3y)Interest Coverage Ratio Growth (5y)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Cash Flow Growth (3y)Net Cash Flow Growth (5y)Net Income (QoQ)Net Income Growth (1y)Net Income Growth (3y)Net Income Growth (5y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Income towards Common Stockholders Growth (3y)Net Income towards Common Stockholders Growth (5y)Net Margin (QoQ)Net Margin Growth (1y)Net Margin Growth (3y)Net Margin Growth (5y)Operating Income (QoQ)Operating Income Growth (1y)Operating Income Growth (3y)Operating Income Growth (5y)Operating Margin (QoQ)Operating Margin Growth (1y)Operating Margin Growth (3y)Operating Margin Growth (5y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Profit After Tax Growth (3y)Profit After Tax Growth (5y)Property, Plant & Equipment (Net) (QoQ)Property, Plant & Equipment (Net) Growth (1y)Property, Plant & Equipment (Net) Growth (3y)Property, Plant & Equipment (Net) Growth (5y)Return on Assets (QoQ)Return on Assets Growth (1y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Sales (QoQ)Return on Sales Growth (1y)Return on Sales Growth (3y)Return on Sales Growth (5y)Revenue (QoQ)Revenue Growth (1y)Revenue Growth (3y)Revenue Growth (5y)Share-based Compensation (QoQ)Share-based Compensation Growth (1y)Share-based Compensation Growth (3y)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)Shareholder's Equity Growth (5y)Total Debt (QoQ)Total Debt Growth (1y)Total Debt Growth (3y)Total Debt Growth (5y)

Others

Novartis Ag (NVS) Capital Expenditures Growth (3y) (2012 - 2026)

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex Growth (3y) (Qtr)
1	Novartis Ag	107,124,802.25 Bn	107,124,802.25 Bn	-	-27.23%
2	Eli Lilly	969.00 Bn	963.72 Bn	16.22 Bn	51.53%
3	Johnson & Johnson	539.46 Bn	517.41 Bn	15.96 Bn	6.72%
4	AbbVie	376.92 Bn	367.57 Bn	10.78 Bn	14.83%
5	Merck	285.00 Bn	279.35 Bn	12.09 Bn	-0.53%
6	Amgen	177.58 Bn	165.55 Bn	5.87 Bn	27.44%
7	Gilead Sciences	163.22 Bn	155.50 Bn	5.52 Bn	2.39%
8	Pfizer	145.86 Bn	133.09 Bn	-1.21 Bn	-27.39%
9	Bristol Myers Squibb	111.90 Bn	101.44 Bn	8.07 Bn	7.67%
10	Gsk	88.34 Bn	83.66 Bn	-	-

Historic Data

Download Data 🔒

Date	Value
Mar 31, 2026	-27.23%
Dec 31, 2025	-25.79%
Sep 30, 2025	-17.00%
Jun 30, 2025	-8.80%
Mar 31, 2025	0.39%
Dec 31, 2024	-6.65%
Sep 30, 2024	2.93%
Jun 30, 2024	6.78%
Mar 31, 2024	2.64%
Dec 31, 2023	7.98%
Sep 30, 2023	2.20%
Jun 30, 2023	1.85%
Mar 31, 2023	10.84%
Dec 31, 2022	12.77%
Sep 30, 2022	14.77%
Jun 30, 2022	2.70%
Mar 31, 2022	3.05%
Dec 31, 2021	-1.19%
Sep 30, 2021	-5.96%
Jun 30, 2021	-7.69%
Mar 31, 2021	1.58%
Dec 31, 2020	6.53%
Sep 30, 2020	9.94%
Jun 30, 2020	10.50%
Mar 31, 2020	11.68%
Dec 31, 2019	7.69%
Sep 30, 2019	6.94%
Jun 30, 2019	14.60%
Mar 31, 2019	9.86%
Dec 31, 2018	16.14%
Sep 30, 2018	20.13%
Jun 30, 2018	-7,586.09%
Mar 31, 2018	-8,093.74%
Dec 31, 2017	-9,060.39%
Sep 30, 2017	-8,200.34%
Jun 30, 2017	-7,918.33%
Mar 31, 2017	-8,836.56%
Sep 30, 2016	-8,257.07%
Jun 30, 2016	-8,811.65%
Mar 31, 2016	-9,084.06%
Sep 30, 2015	-9,463.28%
Jun 30, 2015	2.14%
Mar 31, 2015	-4.41%
Dec 31, 2014	-1.88%
Sep 30, 2014	-9.41%
Jun 30, 2014	-12.44%
Mar 31, 2014	-4.78%
Sep 30, 2013	-29.93%
Jun 30, 2013	-21.26%
Mar 31, 2013	-17.80%
Sep 30, 2012	-16.84%
Jun 30, 2012	-7.59%
Mar 31, 2012	-3.84%